VEA
MLTX icon

Virtus ETF Advisers’s MoonLake Immunotherapeutics MLTX Stock Holding History

Virtus ETF Advisers’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,322
Closed -$71.6K – 642
2024
Q4 		$71.6K Sell
1,322
-840
-39% -$42.9K 0.03% 360
2024
Q3 		$109K Buy
2,162
+42
+2% +$1.97K 0.05% 363
2024
Q2 		$93.2K Buy
2,120
+616
+41% +$26.1K 0.05% 343
2024
Q1 		$75.5K Sell
1,504
-101
-6% -$5.48K 0.04% 399
2023
Q4 		$96.9K Sell
1,605
-2,082
-56% -$107K 0.06% 370
2023
Q3 		$210K Sell
3,687
-366
-9% -$20.2K 0.13% 243
2023
Q2 		$207K Buy
+4,053
New +$109K 0.12% 298

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Virtus ETF Advisers's MLTX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2025, closing a stake of 1,322 shares — an estimated $71.6K sold.

Virtus ETF Advisers first reported a position in MLTX in Q2 2023 and held it in 7 quarters. The position peaked at $210K in Q3 2023. 136 funds tracked by Wall St. Rank hold MLTX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining MoonLake Immunotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,322 MoonLake Immunotherapeutics shares in Q1 2025, an estimated $71.6K.
  • Virtus ETF Advisers first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 7 quarters.
  • Virtus ETF Advisers's MoonLake Immunotherapeutics position peaked at $210K in Q3 2023.
  • 136 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.